Semaglutide's Unstoppable Rise as the 'Drug King'

The development of semaglutide, a miracle drug, is a saga of challenges and breakthroughs. Since it was approved by the US FDA in 2017 for the treatment of type 2 diabetes, its impact has gone beyond diabetes, and now it has been approved in the UK and EU to reduce the risk of cardiovascular death, heart attack and stroke in adults who are overweight or obese and have cardiovascular disease, truly showing the charm of the "drug king".

Select clinical trials, according to data from the department of Meg lu peptide (trade name Wegovy) on the basis of the standard treatment, can significantly reduce the risk of major adverse cardiac events (MACE) in patients with up to 20%. The effect was stable over observation periods of up to 5 years, and the benefit was seen regardless of baseline patient conditions, such as age, sex, race, body mass index (BMI), or renal function status. This finding reveals the broad applicability of semaglutide for the prevention of cardiovascular disease and holds major promise for global public health.

Particularly noteworthy is that peptide in cardiovascular department Meg lu has great market potential in the field of application. According to the World Health Organization, about 18 million people die from cardiovascular disease each year, making it the leading cause of death worldwide. In all cardiovascular disease deaths, MACE events accounted for more than four 5. Therefore, this new indication of semaglutide undoubtedly provides a powerful weapon for the global fight against cardiovascular diseases, and also wins it the competitive position of the global "king of drugs".

However, department of Meg lu peptide potential is far more than that. At present, its research and development company Novo Nordisk has launched more than 100 clinical trials worldwide, covering diabetes, obesity and complications caused by these diseases, such as chronic kidney disease, heart failure, fatty liver and other medical fields. With the deepening of research, we have reason to believe that semaglutide will play an important role in more medical fields and create a more brilliant future for global public health.